171 related articles for article (PubMed ID: 18466802)
1. From black and white to shades of gray: race and renin-angiotensin system blockade.
Havranek EP
J Am Coll Cardiol; 2008 May; 51(19):1872-3. PubMed ID: 18466802
[No Abstract] [Full Text] [Related]
2. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
Prisant LM; Thomas KL; Lewis EF; Huang Z; Francis GS; Weaver WD; Pfeffer MA; McMurray JJ; Califf RM; Velazquez EJ
J Am Coll Cardiol; 2008 May; 51(19):1865-71. PubMed ID: 18466801
[TBL] [Abstract][Full Text] [Related]
3. VALIANT trial results support use of valsartan in acute myocardial infarction.
Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754
[No Abstract] [Full Text] [Related]
4. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Bissessor N; White H
Vasc Health Risk Manag; 2007; 3(4):425-30. PubMed ID: 17969373
[TBL] [Abstract][Full Text] [Related]
5. VALIANT and EUROPA.
Liebson PR
Prev Cardiol; 2004; 7(1):42-4. PubMed ID: 15010627
[No Abstract] [Full Text] [Related]
6. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
[No Abstract] [Full Text] [Related]
7. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
[TBL] [Abstract][Full Text] [Related]
8. Valsartan, captopril, or both in myocardial infarction.
McAnulty JH
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
[No Abstract] [Full Text] [Related]
9. [AT(1) blocker for post-infarct therapy. VALIANT Study].
Hasenfuss G
Internist (Berl); 2004 Aug; 45(8):946-8. PubMed ID: 15252713
[No Abstract] [Full Text] [Related]
10. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
11. Valsartan in acute myocardial infarction trial.
Piña IL
Curr Cardiol Rep; 2004 May; 6(3):159-60. PubMed ID: 15075047
[No Abstract] [Full Text] [Related]
12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
13. Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
Croom KF; Keating GM
Am J Cardiovasc Drugs; 2004; 4(6):395-404. PubMed ID: 15554725
[TBL] [Abstract][Full Text] [Related]
14. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
[TBL] [Abstract][Full Text] [Related]
15. Valsartan in the treatment of heart attack survivors.
Jugdutt BI
Vasc Health Risk Manag; 2006; 2(2):125-38. PubMed ID: 17319456
[TBL] [Abstract][Full Text] [Related]
16. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Miller AB; Srivastava P
Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
[TBL] [Abstract][Full Text] [Related]
18. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
19. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
20. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
MMW Fortschr Med; 2003 Oct; 145(43):51. PubMed ID: 14664222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
